Clinical Trials · NCT07677891
Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus
- Phase
- Phase 2
- Recruitment status
- Not Yet Recruiting
- Sponsor
- ProGen. Co., Ltd.
- Enrollment
- 60
- Start date
- Oct 2026
- Locations
- See registry
- Primary endpoint
- Change in HbA1c from Baseline at Week 32